The briefing
In a phase 1 study, the MVA-vectored neoantigen vaccine TG4050 in resected HPV-negative head and neck cancer showed no dose-limiting toxicities and no relapses among participants reported. Investigators say the early results are encouraging and merit further evaluation.
Original headline
Neoantigen Vaccine Shows Encouraging Activity in Head and Neck Cancer